Article

Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?

Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif 94805, France.
British Journal of Cancer (Impact Factor: 4.82). 01/2009; 99(11):1959. DOI: 10.1038/sj.bjc.6604800
Source: PubMed

ABSTRACT Carcinomas of an unknown primary site (CUP) are heterogeneous tumours with a median survival of only 8 months. Tyrosine kinase inhibitors are promising new drugs. The aim of this study was to determine the expression of EGF-receptor, Her-2/neu, and c-Kit tyrosine kinases in CUP. Paraffin-embedded specimens were obtained from 54 patients with a CUP who were included in the GEFCAPI 01 randomised phase II trial. Immunohistochemistry was performed using the Dako autostainer with antibodies directed against HER-2/neu protein, EGFR protein, and c-Kit protein (CD117). EGFR expression was found in 36 out of 54 samples (66%). In contrast, Her-2/neu overexpression and c-Kit positivity were only detected in 4 and 10% of patients, respectively. No significant association was found between the expression of the tyrosine kinase receptors and prognosis. EGFR expression was significantly associated with response to cisplatin-based chemotherapy: the response rates were 50 and 22% in patients with EGFR-positive tumours and EGFR-negative tumours, respectively (P<0.05). This study shows that EGFR is frequently expressed in CUP. This finding may prompt clinical trials investigating EGFR inhibitors in this setting. In contrast, c-Kit expression and Her-2/neu overexpression occur infrequently in CUP. EGFR expression was correlated to tumour chemosensitivity.

Download full-text

Full-text

Available from: Alain Lortholary, Sep 15, 2014
0 Followers
 · 
121 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Malgréles progrès en imagerie et en immunohistochimie, les carcinomes de primitif inconnu (CAPI) représentent encore 3 à 5% des tumeurs prises en charge en oncologie médicale. Le pronostic effroyable de cette entité, confronté aux progrès rapportés dans lamajorité des cancers de primitif connu liés à l’avènement de thérapeutiques ciblées, invite à s’interroger à nouveau sur les possibilités d’identifier l’origine du CAPI, ou encore, sur les voies du signal susceptibles d’être utilisées comme cibles. Le développement de nouveaux outils, tels que les biopuces à ADN et leurs applications en clinique, pourrait permettre dans le futur de guider le diagnostic et, ainsi, de proposer un traitement spécifique. Dans l’attente de leur évaluation, les CAPI doivent faire l’objet d’essais thérapeutiques testant l’apport des thérapeutiques ciblées. Despite significant progress in imaging and immunohistochemistry, carcinomas of unknown primary (CUP) still account for 3 to 5% of all adult neoplasms. The adverse prognosis of this entity, and the development of targeted therapies, should strengthen efforts to identify the primary tumour or the signal transduction mechanisms that may be drug-targeted. The development of new technologies including DNA-micro-array and their use in clinical practice may potentially be helpful, in the near future, in identifying a primary tumour site, and therefore in determining a specific management. Efforts should be made to accrue clinical trials testing targeted therapies for CUP patients.
    Oncologie 10(12):718-721. DOI:10.1007/s10269-008-0985-1 · 0.08 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Most nonlinear dynamics and chaos literature is written either for readers of popular science magazines or for advanced mathematicians. This paper gives a broad introduction to this interesting and rapidly growing field at a level that is between the two. The graphical and analytical tools used in the literature are explained, a brief outline of the current theory is given, and that theory is illustrated with several examples: an electronic circuit, a chemical reaction and a system of satellites in the solar system.
    Computers & Graphics 09/1995; DOI:10.1016/0097-8493(95)00057-7 · 1.03 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Carcinomas of unknown primary site (CUP) are epithelial malignancies revealed by metastatic lesions in the absence of any detectable primary tumor. Although they often adopt an aggressive clinical pattern, their basic biology remains poorly understood. Laboratory research on their biology have been hampered so far by the absence of cell lines representative of CUPs. We attempted xenografts of CUP clinical specimens in immunodeficient mice and subsequent in vitro culture of transplanted malignant cells. Whenever possible, malignant xenografted or cultured cells were characterized by microsatellite genotyping, immunohistology, electron microscopy, multifish chromosome analysis and search of TP 53 gene mutations. Successful xenografts were achieved in 2 cases out of 4. One of them (Capi1) was lost after 3 passages whereas the other one (Capi3) has been adapted to in vitro culture and is currently available to the scientific community with reliable identification based on microsatellite genotyping. Both Capi1 and Capi3 have histological characteristics of adenocarcinomas and display intense expression of EMA, CEA and cytokeratin 7. Multifish chromosome analysis demonstrated a translocation involving chromosomes 4 and 21 in both specimens. Distinct rare missense mutations of the TP53 gene were detected in Capi1 (codon 312) and Capi3 (codon 181); the codon 181 mutation is consistent with a previously reported similar finding in a small series of CUP specimens. Finally, intense membrane expression of c-kit was recorded in Capi3. Our data suggest that xenografted tumors can be obtained from a substantial fraction of CUP clinical specimens. The hypothesis of a preferential association of CUPs with TP 53 mutations of codon 181 deserves further investigations. The Capi3 cell line will be a useful tool for assessment of novel c-kit inhibitors.
    BMC Cancer 02/2007; 7:225. DOI:10.1186/1471-2407-7-225 · 3.32 Impact Factor